Pipobroman

哌泊溴烷

Report date: 2022/03/23 14:30:06
NME

Base Information

Drug NamePipobroman
Drug Alias Namepipobroman哌酰溴烷溴丙哌嗪pipobromanumVercyte +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsLeukemia, Myelogenous, Chronic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1966/07/01
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott Laboratories
Active IndicationsN/A
Inactive IndicationsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeL01AX02
Related LinksWikipediaDrugBankKEGG